Monday, September 28, 2009

Pralatrexate gets FDA approval....

We did know that Pralatrexate, also known as 10-propargyl- 10-deazaaminopterin, common name PDX, is a drug candidate being studied for the treatment of cancer. PDX is a Folate Anolog Inhibitor of dihydrofolate reductase. As of August 2008, it is undergoing Phase II clinical trials for the treatment of Hodgkin & Nonhodgkin lymphoma (including T -cell lymphoma), non-small cell lung cancer (NSCLC), and bladder cancer.

Now FDA has approved this drug. So at last, patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) will breathe a sigh of relief. FOLOTYN (Pralatrexate) is the first and only drug approved by the FDA for this indication and represents a new treatment option for patients with relapsed or refractory PTCL. This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated. Allos expects to make FOLOTYN available to patients in the U.S. in October.

More info...

No comments:

Post a Comment